BCM
MRNA icon

BlueCrest Capital Management’s Moderna MRNA Stock Holding History

BlueCrest Capital Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,000
Closed -$517K – 230
2022
Q1 		$517K Buy
+3,000
New +$505K 0.02% 209
2020
Q3 		– Sell
-10,206
Closed -$655K – 324
2020
Q2 		$655K Buy
+10,206
New +$559K 0.03% 176

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlueCrest Capital Management's MRNA Position: Q2 2022 in Review

BlueCrest Capital Management sold out of Moderna (MRNA) in Q2 2022, closing a stake of 3,000 shares — an estimated $517K sold.

BlueCrest Capital Management first reported a position in MRNA in Q2 2020 and held it in 2 quarters. The position peaked at $655K in Q2 2020. 981 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • BlueCrest Capital Management reported no remaining Moderna position as of Q2 2022 after selling out during the quarter.
  • BlueCrest Capital Management sold 3,000 Moderna shares in Q2 2022, an estimated $517K.
  • BlueCrest Capital Management first reported a position in Moderna in Q2 2020 and held it in 2 quarters.
  • BlueCrest Capital Management's Moderna position peaked at $655K in Q2 2020.
  • 981 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on BlueCrest Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.